[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].
作者信息
Quesada Stanislas, Vaflard Pauline
机构信息
Institut du cancer de Montpellier (ICM), 208, avenue des Apothicaires - Parc Euromédecine, 34298 Montpellier cedex 5, France.
Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
出版信息
Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.
PMID:34998526
Abstract
摘要
Zotero 插件